Search Results - "JESELSOHN, Rinath"

ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer by Jeselsohn, Rinath, Buchwalter, Gilles, De Angelis, Carmine, Brown, Myles, Schiff, Rachel

“…Key Points Over the past 18 months, recurrent activating mutations within the oestrogen receptor α (ER) LBD have been detected in 15–20% of patients with…”
Get full text

ESR1 fusions and therapeutic resistance in metastatic breast cancer by Nagy, Zsuzsanna, Jeselsohn, Rinath

“…Breast cancer is the most frequent female malignant tumor, and the leading cause of cancer death in women worldwide. The most common subtype of breast cancer…”
Get full text

Corrigendum: ESR1 fusions and therapeutic resistance in metastatic breast cancer by Nagy, Zsuzsanna, Jeselsohn, Rinath

“…[This corrects the article DOI: 10.3389/fonc.2022.1037531.]…”
Get full text

Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer by Tarantino, Paolo, Jin, Qingchun, Tayob, Nabihah, Jeselsohn, Rinath M, Schnitt, Stuart J, Vincuilla, Julie, Parker, Tonia, Tyekucheva, Svitlana, Li, Tianyu, Lin, Nancy U, Hughes, Melissa E, Weiss, Anna C, King, Tari A, Mittendorf, Elizabeth A, Curigliano, Giuseppe, Tolaney, Sara M

“…It is unclear whether ERBB2-low breast cancer should be considered an individual biologic subtype distinct from ERBB2-0 breast cancer. To investigate whether…”
Get more information

VIPER: Visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis by Cornwell, MacIntosh, Vangala, Mahesh, Taing, Len, Herbert, Zachary, Köster, Johannes, Li, Bo, Sun, Hanfei, Li, Taiwen, Zhang, Jian, Qiu, Xintao, Pun, Matthew, Jeselsohn, Rinath, Brown, Myles, Liu, X Shirley, Long, Henry W

“…RNA sequencing has become a ubiquitous technology used throughout life sciences as an effective method of measuring RNA abundance quantitatively in tissues and…”
Get full text

The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer by Jeselsohn, Rinath, De Angelis, Carmine, Brown, Myles, Schiff, Rachel

“…Recurrent ligand-binding domain ESR1 mutations have recently been detected in a substantial number of patients with metastatic ER+ breast cancer and evolve…”
Get full text

Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations by Jeselsohn, Rinath, Bergholz, Johann S., Pun, Matthew, Cornwell, MacIntosh, Liu, Weihan, Nardone, Agostina, Xiao, Tengfei, Li, Wei, Qiu, Xintao, Buchwalter, Gilles, Feiglin, Ariel, Abell-Hart, Kayley, Fei, Teng, Rao, Prakash, Long, Henry, Kwiatkowski, Nicholas, Zhang, Tinghu, Gray, Nathanael, Melchers, Diane, Houtman, Rene, Liu, X. Shirley, Cohen, Ofir, Wagle, Nikhil, Winer, Eric P., Zhao, Jean, Brown, Myles

“…Estrogen receptor α (ER) ligand-binding domain (LBD) mutations are found in a substantial number of endocrine treatment-resistant metastatic ER-positive (ER+)…”
Get full text

Estrogen receptor signaling is reprogrammed during breast tumorigenesis by Chi, David, Singhal, Hari, Li, Lewyn, Xiao, Tengfei, Liu, Weihan, Pun, Matthew, Jeselsohn, Rinath, He, Housheng, Lim, Elgene, Vadhi, Raga, Rao, Prakash, Long, Henry, Garber, Judy, Brown, Myles

“…Limited knowledge of the changes in estrogen receptor (ER) signaling during the transformation of the normal mammary gland to breast cancer hinders the…”
Get full text

Estrogen-regulated feedback loop limits the efficacy of estrogen receptor–targeted breast cancer therapy by Xiao, Tengfei, Li, Wei, Wang, Xiaoqing, Xu, Han, Yang, Jixin, Wu, Qiu, Huang, Ying, Geradts, Joseph, Jiang, Peng, Fei, Teng, Chi, David, Zang, Chongzhi, Liao, Qi, Rennhack, Jonathan, Andrechek, Eran, Li, Nanlin, Detre, Simone, Dowsett, Mitchell, Jeselsohn, Rinath M., Liu, Shirley, Brown, Myles

“…Endocrine therapy resistance invariably develops in advanced estrogen receptor-positive (ER⁺) breast cancer, but the underlying mechanisms are largely unknown…”
Get full text

The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells by Fanning, Sean W, Jeselsohn, Rinath, Dharmarajan, Venkatasubramanian, Mayne, Christopher G, Karimi, Mostafa, Buchwalter, Gilles, Houtman, René, Toy, Weiyi, Fowler, Colin E, Han, Ross, Lainé, Muriel, Carlson, Kathryn E, Martin, Teresa A, Nowak, Jason, Nwachukwu, Jerome C, Hosfield, David J, Chandarlapaty, Sarat, Tajkhorshid, Emad, Nettles, Kendall W, Griffin, Patrick R, Shen, Yang, Katzenellenbogen, John A, Brown, Myles, Greene, Geoffrey L

“…Acquired resistance to endocrine therapy remains a significant clinical burden for breast cancer patients. Somatic mutations in the (estrogen receptor alpha…”
Get full text

FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer by Fu, Xiaoyong, Pereira, Resel, De Angelis, Carmine, Veeraraghavan, Jamunarani, Nanda, Sarmistha, Qin, Lanfang, Cataldo, Maria L., Sethunath, Vidyalakshmi, Mehravaran, Sepideh, Gutierrez, Carolina, Chamness, Gary C., Feng, Qin, O’Malley, Bert W., Selenica, Pier, Weigelt, Britta, Reis-Filho, Jorge S., Cohen, Ofir, Wagle, Nikhil, Nardone, Agostina, Jeselsohn, Rinath, Brown, Myles, Rimawi, Mothaffar F., Osborne, C. Kent, Schiff, Rachel

“…Forkhead box A1 (FOXA1) is a pioneer factor that facilitates chromatin binding and function of lineage-specific and oncogenic transcription factors…”
Get full text

Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis by Wu, Yanming, Zhang, Zhao, Cenciarini, Mauro E, Proietti, Cecilia J, Amasino, Matias, Hong, Tao, Yang, Mei, Liao, Yiji, Chiang, Huai-Chin, Kaklamani, Virginia G, Jeselsohn, Rinath, Vadlamudi, Ratna K, Huang, Tim Hui-Ming, Li, Rong, De Angelis, Carmine, Fu, Xiaoyong, Elizalde, Patricia V, Schiff, Rachel, Brown, Myles, Xu, Kexin

“…Resistance to cancer treatment can be driven by epigenetic reprogramming of specific transcriptomes in favor of the refractory phenotypes. Here we discover…”
Get full text

Temporal and spatial topography of cell proliferation in cancer by Gaglia, Giorgio, Kabraji, Sheheryar, Rammos, Danae, Dai, Yang, Verma, Ana, Wang, Shu, Mills, Caitlin E., Chung, Mirra, Bergholz, Johann S., Coy, Shannon, Lin, Jia-Ren, Jeselsohn, Rinath, Metzger, Otto, Winer, Eric P., Dillon, Deborah A., Zhao, Jean J., Sorger, Peter K., Santagata, Sandro

“…Proliferation is a fundamental trait of cancer cells, but its properties and spatial organization in tumours are poorly characterized. Here we use highly…”
Get full text

How drug resistance takes shape by Jeselsohn, Rinath, Brown, Myles

“…Mutations in a hormone receptor can lead to therapeutic resistance by making it less able to bind and respond to hormone blocking drugs and by making it…”
Get full text

FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer by Fu, Xiaoyong, Jeselsohn, Rinath, Pereira, Resel, Hollingsworth, Emporia F., Creighton, Chad J., Li, Fugen, Shea, Martin, Nardone, Agostina, De Angelis, Carmine, Heiser, Laura M., Anur, Pavana, Wang, Nicholas, Grasso, Catherine S., Spellman, Paul T., Griffith, Obi L., Tsimelzon, Anna, Gutierrez, Carolina, Huang, Shixia, Edwards, Dean P., Trivedi, Meghana V., Rimawi, Mothaffar F., Lopez-Terrada, Dolores, Hilsenbeck, Susan G., Gray, Joe W., Brown, Myles, Osborne, C. Kent, Schiff, Rachel

“…Forkhead box protein A1 (FOXA1) is a pioneer factor of estrogen receptor α (ER)–chromatin binding and function, yet its aberration in endocrine-resistant…”
Get full text

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib by Coombes, R. C., Howell, Sacha, Lord, Simon R., Kenny, Laura, Mansi, Janine, Mitri, Zahi, Palmieri, Carlo, Chap, Linnea I., Richards, Paul, Gradishar, William, Sardesai, Sagar, Melear, Jason, O’Shaughnessy, Joyce, Ward, Patrick, Chalasani, Pavani, Arkenau, Tobias, Baird, Richard D., Jeselsohn, Rinath, Ali, Simak, Clack, Glen, Bahl, Ashwani, McIntosh, Stuart, Krebs, Matthew G.

“…Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with…”
Get full text

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer by Keenan, Tanya E., Guerriero, Jennifer L., Barroso-Sousa, Romualdo, Li, Tianyu, O’Meara, Tess, Giobbie-Hurder, Anita, Tayob, Nabihah, Hu, Jiani, Severgnini, Mariano, Agudo, Judith, Vaz-Luis, Ines, Anderson, Leilani, Attaya, Victoria, Park, Jihye, Conway, Jake, He, Meng Xiao, Reardon, Brendan, Shannon, Erin, Wulf, Gerburg, Spring, Laura M., Jeselsohn, Rinath, Krop, Ian, Lin, Nancy U., Partridge, Ann, Winer, Eric P., Mittendorf, Elizabeth A., Liu, David, Van Allen, Eliezer M., Tolaney, Sara M.

“…Immune checkpoint inhibitors (ICIs) have minimal therapeutic effect in hormone receptor-positive (HR+ ) breast cancer. We present final overall survival (OS)…”
Get full text

Osteopontin is a therapeutic target that drives breast cancer recurrence by Gu, Yu, Taifour, Tarek, Bui, Tung, Zuo, Dongmei, Pacis, Alain, Poirier, Alexandre, Attalla, Sherif, Fortier, Anne-Marie, Sanguin-Gendreau, Virginie, Pan, Tien-Chi, Papavasiliou, Vasilios, Lin, Nancy U., Hughes, Melissa E., Smith, Kalie, Park, Morag, Tremblay, Michel L., Chodosh, Lewis A., Jeselsohn, Rinath, Muller, William J.

“…Recurrent breast cancers often develop resistance to standard-of-care therapies. Identifying targetable factors contributing to cancer recurrence remains the…”
Get full text

Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer by Tarantino, Paolo, Gupta, Hersh, Hughes, Melissa E., Files, Janet, Strauss, Sarah, Kirkner, Gregory, Feeney, Anne-Marie, Li, Yvonne, Garrido-Castro, Ana C., Barroso-Sousa, Romualdo, Bychkovsky, Brittany L., DiLascio, Simona, Sholl, Lynette, MacConaill, Laura, Lindeman, Neal, Johnson, Bruce E., Meyerson, Matthew, Jeselsohn, Rinath, Qiu, Xintao, Li, Rong, Long, Henry, Winer, Eric P., Dillon, Deborah, Curigliano, Giuseppe, Cherniack, Andrew D., Tolaney, Sara M., Lin, Nancy U.

“…The molecular underpinnings of HER2-low and HER2-0 (IHC 0) breast tumors remain poorly defined. Using genomic findings from 1039 patients with HER2-negative…”
Get full text

Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer by Tarantino, Paolo, Gupta, Hersh, Hughes, Melissa E., Files, Janet, Strauss, Sarah, Kirkner, Gregory, Feeney, Anne-Marie, Li, Yvonne, Garrido-Castro, Ana C., Barroso-Sousa, Romualdo, Bychkovsky, Brittany L., DiLascio, Simona, Sholl, Lynette, MacConaill, Laura, Lindeman, Neal, Johnson, Bruce E., Meyerson, Matthew, Jeselsohn, Rinath, Qiu, Xintao, Li, Rong, Long, Henry, Winer, Eric P., Dillon, Deborah, Curigliano, Giuseppe, Cherniack, Andrew D., Tolaney, Sara M., Lin, Nancy U.

Get full text